OHAMR Call for proposals 2026

General Information

• Type: Partner looking for project
• Organisation: MGP
• Country: France (FR)
• Career stage: Other.

Research area

• Scientific area(s) of the call:
  1. Topic 1: Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
• One Health Setting:

  H - Human Health

  A - Animal Health

• Keywords:

  Microbiota; Microbiome; Fermenter; Sequencing; Functional Screening

• Brief description of your expertise / expertise you are looking for:

  Metagenopolis, an INRAE research unit expert in Gut microbiome science applied to human and animal health and nutrition, offers platforms and technologies that map microbiota and characterize its function: • High-Throughput Quantitative Metagenomics (WGS): Deep, strain-level profiling with functional annotation, backed by expert biostatistics and bioinformatics. By comparing microbial signatures in healthy versus infectios diseases patients, our mapping tool can identify microbiome “neighborhoods” with high precision, facilitating more efficient next-generation probiotic and microbial consortium design • Fermenter System – A human-relevant ex vivo gut model to study product–microbiota interactions under conditions such as antibiotic exposure, pathogen influence, or antimicrobial/microbiome therapies. It helps assess product efficacy, toxicity and its impact on microbiome, supporting development of compounds that limit resistance. • Functional Cell-Based Screening – Host–microbiota assays to evaluate gut barrier integrity and immune responses to new antibiotics or biotherapeutics, enabling earlier de-risking of candidates before clinical trials. • The French Gut Database – Over 10,000 sequenced participants (of a planned 100,000) with extensive dietary and clinical metadata. This enables mapping of AMR genes and microbiome signatures linked to environmental and nutritional factors, chronic infections, antibiotic exposure and resistance risk, as well testing microbial therapeutics on selected cohorts.

• Brief description of your project / the project you would like to join:

  To develop a next-generation microbial consortium as a novel antimicrobial intervention targeting AMR-associated pathogens. The consortium will be evaluated through a full preclinical and translational pipeline, including ex vivo gut fermenter experiments to assess microbiome integration, antimicrobial efficacy, pathogen suppression, AMR gene reduction, and toxicity and safety profiles. Complementary functional cell-based screening will characterize mechanisms of action such as epithelial barrier protection, immune modulation, and anti-inflammatory effects. Successful candidates will advance to clinical or in vivo studies to validate efficacy in reducing infection incidence and antibiotic use.

Dina Chokr: dina.chokr@inrae.fr

• Organisation: MGP
• Position: Business developer
• E-mail: dina.chokr@inrae.fr
• Web: mgps.eu/